biomarkers news from FierceBiotech
News
Battelle Ventures, Apax Partners spin off companies
There are two new spin-offs to announce today. First, Battelle Ventures has spun out regenerative medicine start-up NellOne Therapeutics from the U.S. Department of Energy's Oak Ridge National Read more...
FDA ready to start adding biomarker safety tests
The San Francisco Chronicle is reporting that the FDA is prepared to back a new safety standard on preclinical drugs that could--at some point--significantly reduce the time and expense of testing a Read more...
ALSO NOTED: Millipore CEO gains $3.9M comp package;Terminal cancer patients enlisted in trials; and much more...
> It may not rival the big bucks earned by Big Pharma CEOs, but Millipore chief exec Martin Madaus took home a hefty pay package last year. He earned $3.9 million in compensation in 2007. That Read more...
Genizon pockets $31M CAD in fifth round
Canada's Genizon BioSciences has garnered $31 million Canadian in its fifth round of financing. The lead investor is BTF B.V. of Haarlem, The Netherlands, which specializes in late-stage biotech Read more...
ALSO NOTED: Houston develop plots biotech park; Galvus wins EU nod; OncoMethylome inks deal with Abbott; and much more...
> A Houston developer has acquired Tanox's old headquarters--110,000 square feet on 24 acres--and plans to develop it as a biotechnology park. Tanox developed the asthma drug Xolair. Read more...
Biomarker company gains $25M in fresh backing
Rules-Based Medicine, which is hot in pursuit of new biomarkers, has received a $25 million injection of cash. Part of that money is coming from real estate billionaire Sam Zell, who is putting his Read more...
Wyeth drops Karo Bio atherosclerosis drug
Karo Bio and research partner Wyeth Pharmaceuticals have abandon development of LXR-623, a Phase I compound for atherosclerosis. According to a release, LXR-623 demonstrated efficacy on biomarkers Read more...
ALSO NOTED: Indevus gains $50M payday; Genzyme settles suit; AnGes submits ERT; and much more...
> Indevus has snared a $49.9 million milestone payment following the FDA's approval of Sanctura XR. Read more...
Press Release: Adnexus Therapeutics Announces Presentation of Phase I Results for CT-322
Press Release: Adnexus Therapeutics Announces Presentation of Phase I Results for CT-322
Read more...ALSO NOTED: Feds ask Genentech for more merger info; Japan confirms bird flu outbreak; and much more...
> The FTC has asked for more information about Genentech's proposed merger with Tanox. Report
> Japan has confirmed the third outbreak of avian flu in poultry. Report
> The head of ArQule's scientific advisory …
Read more...Get more biomarkers coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets